<DOC>
	<DOCNO>NCT00002516</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one drug surgery radiation therapy may kill tumor cell . It yet know combination chemotherapy regimen effective treat patient Ewing 's sarcoma . PURPOSE : Randomized phase III trial compare various combination chemotherapy regimens plus surgery radiation therapy treat patient Ewing 's sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Surgery Radiation Therapy Treating Patients With Ewing 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether morbidity reduce preserve survival substitute cyclophosphamide ifosfamide adjuvant combination chemotherapy standard-risk patient Ewing 's sarcoma peripheral neuroectodermal tumor ( PNET ) . II . Determine whether survival improve without unacceptable toxicity high-risk patient Ewing 's sarcoma PNET addition etoposide VAIA regimen ( vincristine/doxorubicin/ifosfamide/dactinomycin ) . III . Evaluate impact surgery conventional vs. hyperfractionated radiotherapy ( definitive adjuvant ) local control , overall survival , morbidity patient . IV . Relate treatment outcome patient characteristic , histologic subtype diagnosis , histologic response neoadjuvant treatment . V. Evaluate prospectively ifosfamide-induced nephrotoxicity doxorubicin-induced cardiotoxicity . OUTLINE : Randomized study . Patients initially stratify STANDARD RISK ( tumor volume diagnosis &lt; 100 ml ) HIGH RISK ( tumor volume diagnosis least 100 ml , &lt; 100 ml , metastasis present ) . All patient receive 14 course chemotherapy , administer q 3 week throughout protocol treatment . Standard-risk patient receive 4 course NEOADJUVANT CHEMOTHERAPY Regimen A , high-risk patient randomize Arms I II 4 course neoadjuvant chemotherapy . LOCAL THERAPY usually initiate week 12 , 4 course neoadjuvant chemotherapy , consist either total removal tumor-bearing compartment , intracompartmental surgery ( without adjuvant radiotherapy ) , definitive radiotherapy alone ; choice dictate site , tumor size , patient age , among variable . Postoperatively , patient receive 10 course ADJUVANT CHEMOTHERAPY ( plus adjuvant radiotherapy give ) ; standard-risk patient randomize Arms III IV , high-risk patient receive regimen assign initial randomization . When give , adjuvant radiotherapy begin week 19 administer concurrently chemotherapy . As variant general plan , patient &lt; 50 % regression soft tissue component tumor restaging 2 course neoadjuvant chemotherapy ( slow response ) may receive preoperative irradiation , begin week 7 , concomitantly third fourth course chemotherapy . The following acronym use : CTX Cyclophosphamide , NSC-26271 DACT Dactinomycin , NSC-3053 DOX Doxorubicin , NSC-123127 IFF Ifosfamide , NSC-109724 Mesna Mercaptoethane sulfonate , NSC-113891 VCR Vincristine , NSC-67574 VP-16 Etoposide , NSC-141540 NEOADJUVANT CHEMOTHERAPY . Regimen A ( Standard risk ) : Alternating 3-Drug Combination Chemotherapy Regimens . VAIA : VCR/DOX/IFF alternate VCR/DACT/IFF . Arm I ( High risk ) : Alternating 3-Drug Combination Chemotherapy Regimens . VAIA : VCR/DOX/IFF alternate VCR/DACT/IFF . Arm II ( High-risk ) : Alternating 4-Drug Combination Chemotherapy Regimens . EVAIA : VP-16/VCR/DOX/IFF alternate VP-16/VCR/DACT/IFF . LOCAL THERAPY . Surgery : Resection entire tumor-bearing compartment , include bone soft tissue , possible , treatment choice . The range possible surgical procedure include : radical resection ( e.g. , amputation ) , wide resection ( en bloc removal entire tumor-bearing compartment ) , marginal surgery ( en bloc removal , resection line run pseudocapsule microscopic residual disease likely ) , intralesional resection ( tumor incise contamination surgical field ) , resection . Radiotherapy : There 3 setting radiotherapy deliver patient : definitive treatment definitive surgery feasible , postoperative adjuvant treatment , preoperatively patient slow response neoadjuvant chemotherapy . Patients receive definitive postoperative adjuvant treatment randomize conventional fractionation hyperfractionated accelerated split-course delivery ; individual receive preoperative irradiation randomize radiotherapy schedule assign nonrandomly receive hyperfractionated accelerated split-course scheme ( conventional fractionation require DOX DACT eliminate concomitant chemotherapy , whereas agent continue hyperfractionated schedule ) . Individual institution may elect randomize radiotherapy fractionation scheme , i.e. , treat patient one schedule ; institution , patient must follow scheme , decide upon prior treatment first patient . Use photon energies 4-6 MV ( include Co60 ) recommend extremity lesion , 6-15 MV energy recommend trunk lesion ; electron may consider small superficial boost , adequate sole modality . ADJUVANT THERAPY . Arm III ( Standard risk ) : Alternating 3-Drug Combination Chemotherapy Regimens . VACA : VCR/DOX/CTX alternate VCR/DACT/CTX . Arm IV ( Standard risk ) : Alternating 3-Drug Combination Chemotherapy Regimens . VAIA : VCR/DOX/IFF alternate VCR/DACT/IFF . High-risk patient continue 10 additional course VAIA EVAIA accord original randomization . Adjuvant Radiotherapy , administer , begin week 19 , give concomitantly chemotherapy . PROJECTED ACCRUAL : It anticipate 600 patient ( 200 standard-risk 400 high-risk ) accrue 4 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven Ewing 's sarcoma , atypical Ewing 's sarcoma , peripheral neuroectodermal tumor No soft tissue Ewing 's sarcoma small cell sarcoma soft tissue Such patient treat appropriate national Soft Tissue Sarcoma Protocol Treatment must begin within 3 week diagnostic biopsy Registration must occur within 6 week initiation treatment PATIENT CHARACTERISTICS : Age : Not 35 PRIOR CONCURRENT THERAPY : No prior therapy , include primary definitive local therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>